MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

See also
Status	Clinical Trial	Phase
Completed	`NCT03376464` - Xeomin Cosmetic in the Management of Masseter	Phase 4
Not yet recruiting	`NCT06408766` - Investigating the Effects of Smartphone Use on the Masseter Muscle
Completed	`NCT02010775` - Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy	Phase 2
Recruiting	`NCT06343194` - Changes in Electromyographic Activity in Aligner Treatment of Adult Patients With and Without Nocturnal Bruxism	N/A

See also

Status

Clinical Trial

Phase

Completed

NCT03376464 - Xeomin Cosmetic in the Management of Masseter

Phase 4

Not yet recruiting

NCT06408766 - Investigating the Effects of Smartphone Use on the Masseter Muscle

Completed

NCT02010775 - Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy

Phase 2

Recruiting

NCT06343194 - Changes in Electromyographic Activity in Aligner Treatment of Adult Patients With and Without Nocturnal Bruxism

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03452345
Study type	Interventional
Source	Medy-Tox
Contact
Status	Completed
Phase	Phase 3
Start date	April 9, 2018
Completion date	April 16, 2019

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms